CPHI China 2025 Wrap-up: Lianhe Aigen Engages Global Partners, Forging Pharma Innovation

The 23rd CPHI China 2025 concluded successfully on June 26 at Shanghai New International Expo Center! This premier three-day event gathered 3,500+ leading companies and 100,000+ professional visitors worldwide, spotlighting cutting-edge innovations and shaping the future of pharma through global collaboration.

As an innovation-driven CDMO with deep pharmaceutical expertise, Lianhe Aigen showcased its competitive edge through a dedicated team of business and technical experts.

Throughout the exhibition, we engaged in in-depth discussions with global partners, highlighting our end-to-end solutions spanning:

•          Drug Synthesis

•          Process Development & Optimization

•          Quality Control

•          Regulatory Validation

•          Commercial Manufacturing

Our interactions demonstrated Lianhe Aigen’s strengths in technology innovation and precision project management, paving the way for future collaborations.

Though the event has ended, our commitment continues. Upholding our mission of

"Empower Global Drug Innovation, Advance Human Health", we prioritize SHEQ&C-first values and deliver reliable, customer-centric CDMO services for mutual growth.

Let's continue the journey together at CPHI Frankfurt 2025!